tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IKT Stock Latest News

Inhibikase Therapeutics initiated with a Buy at BofA
The FlyInhibikase Therapeutics initiated with a Buy at BofA
16d ago
IKT
Dynavax, Inhibikase and More: Stocks Trending by Analysts
PremiumWeekend Updates
Dynavax, Inhibikase and More: Stocks Trending by Analysts
1M ago
IKT
DVAX
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
PremiumRatings
Inhibikase Therapeutics: Late-Stage IKT-001 PAH Program and De-Risked 505(b)(2) Pathway Support Buy Rating and $8 Target
1M ago
IKT
Inhibikase Updates ATM Equity Program to Raise Capital
PremiumCompany Announcements
Inhibikase Updates ATM Equity Program to Raise Capital
2M ago
8K
IKT
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
IKT
Inhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
PremiumRatingsInhibikase Therapeutics: Advancing IKT-001 to Revolutionize PAH Treatment and Capture Multi-Billion-Dollar Market
2M ago
IKT
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
Premium
Company Announcements
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress
2M ago
IKT
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
Premium
Company Announcements
Inhibikase Therapeutics Announces $93.6 Million Stock Offering
3M ago
8K
IKT
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
PremiumThe Fly
Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45
3M ago
IKT
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
PremiumThe Fly
Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45
3M ago
IKT
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study
PremiumCompany Announcements
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study
3M ago
8K
IKT
Inhibikase announces common stock and warrants offering, no amount given
PremiumThe Fly
Inhibikase announces common stock and warrants offering, no amount given
3M ago
IKT
Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
PremiumThe FlyInhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH
3M ago
IKT
Inhibikase Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating
Premium
Ratings
Inhibikase Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating
3M ago
IKT
Inhibikase Therapeutics: Strong Financial Position and Strategic Advancements Drive Buy Rating
Premium
Ratings
Inhibikase Therapeutics: Strong Financial Position and Strategic Advancements Drive Buy Rating
6M ago
IKT
Inhibikase Therapeutics appoints Pigot as Chief Commercial, Strategy Officer
PremiumThe Fly
Inhibikase Therapeutics appoints Pigot as Chief Commercial, Strategy Officer
6M ago
IKT
Inhibikase Therapeutics Reports Q2 2025 Financials and Progress
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q2 2025 Financials and Progress
6M ago
IKT
Inhibikase Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Inhibikase Therapeutics Reports Q2 2025 Financial Results
6M ago
8K
IKT
Inhibikase Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany Announcements
Inhibikase Therapeutics Approves Key Proposals at Annual Meeting
7M ago
8K
IKT
Inhibikase Therapeutics files $300M mixed securities shelf
PremiumThe FlyInhibikase Therapeutics files $300M mixed securities shelf
8M ago
IKT
Inhibikase Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Inhibikase Therapeutics Reports Q1 2025 Financial Results
9M ago
IKT
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating
Premium
Ratings
Inhibikase Therapeutics: Strategic Realignment and Financial Strength Justify Buy Rating
9M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >